STA-1474

STA-1474 is an orally active and highly selective HSP90 inhibitor. STA-1474 can trigger tumor cell apoptosis. STA-1474 demonstrates significant antitumor efficacy in spontaneous canine cancer models (e.g., osteosarcoma, thyroid carcinoma) . STA-1474 is promising for research of solid tumors (e.g., osteosarcoma, breast cancer) and HSP90-driven cancers[1][2].

Product Specifications

CAS Number

[1118915-78-8]

UNSPSC

12352005

Target

HSP

Related Pathways

Cell Cycle/DNA Damage; Metabolic Enzyme/Protease

Field of Research

Cancer

Smiles

O=C1NN=C(C2=CC(C(C)C)=C(OP(O)(O)=O)C=C2O)N1C3=CC4=C(N(C)C=C4)C=C3

Molecular Formula

C20H21N4O6P

Molecular Weight

444.38

References & Citations

[1]McCleese JK, Bear MD, Fossey SL, Mihalek RM, Foley KP, Ying W, Barsoum J, London CA. The novel HSP90 inhibitor STA-1474 exhibits biologic activity against osteosarcoma cell lines. Int J Cancer. 2009 Dec 15;125 (12) :2792-801.|[2]London CA, et al. Phase I evaluation of STA-1474, a prodrug of the novel HSP90 inhibitor ganetespib, in dogs with spontaneous cancer. PLoS One. 2011;6 (11) :e27018.